Lahiru Russell1, Anna Ugalde2, Liliana Orellana3, Donna Milne4, Meinir Krishnasamy5,6, Richard Chambers7, David W Austin8, Patricia M Livingston2. 1. School of Nursing and Midwifery, Faculty of Health, Deakin University, Geelong, Victoria, Australia. l.russell@deakin.edu.au. 2. School of Nursing and Midwifery, Faculty of Health, Deakin University, Geelong, Victoria, Australia. 3. Biostatistics Unit, Faculty of Health, Deakin University, Geelong, Australia. 4. Skin and Melanoma Services/Department of Cancer Experiences Research, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia. 5. Department of Nursing, School of Health Sciences, University of Melbourne, Melbourne, Victoria, Australia. 6. Victorian Comprehensive Cancer Centre, Melbourne, Victoria, Australia. 7. Campus Community Division, Monash University, 40 Exhibition Walk, Clayton, Victoria, 3800, Australia. 8. School of Psychology, Faculty of Health, Deakin University, Geelong, Victoria, Australia.
Abstract
PURPOSE: This study assessed the feasibility and acceptability of an online mindfulness-based intervention (MBI) for people diagnosed with melanoma. The potential benefit of the MBI on fear of cancer recurrence (FCR), worry, rumination, perceived stress and trait mindfulness was also explored. METHODS: Participants who have completed treatment for stage 2c or3 melanoma were recruited from an outpatient clinic and randomly allocated to either the online MBI (intervention) or usual care (control). The 6-week online MBI comprised short videos, daily guided meditations and automated email reminders. Participants were asked to complete questionnaires at baseline and at 6-week post-randomisation. Study feasibility and acceptability were assessed through recruitment rates, retention and participant feedback. Clinical and psychosocial outcomes were compared between groups using linear mixed models. RESULTS:Sixty-nine (58%) eligible participants were randomised (46 in the intervention; 23 in the control group); mean age was 53.4 (SD 13.1); 54% were female. Study completion rate across both arms was 80%. The intervention was found helpful by 72% of the 32 respondents. The intervention significantly reduced the severity of FCR compared to the control group (mean difference = - 2.55; 95% CI - 4.43, - 0.67; p = 0.008). There was no difference between the intervention and control groups on any of the outcome measures. CONCLUSIONS: This online MBI was feasible and acceptable by people at high risk of melanoma recurrence. It significantly reduced FCR severity in this sample. Patients valued accessing the program at their own pace and convenience. This self-guided intervention has the potential to help survivors cope with emotional difficulties. An adequately powered randomised controlled trial to test study findings is warranted.
RCT Entities:
PURPOSE: This study assessed the feasibility and acceptability of an online mindfulness-based intervention (MBI) for people diagnosed with melanoma. The potential benefit of the MBI on fear of cancer recurrence (FCR), worry, rumination, perceived stress and trait mindfulness was also explored. METHODS:Participants who have completed treatment for stage 2c or 3 melanoma were recruited from an outpatient clinic and randomly allocated to either the online MBI (intervention) or usual care (control). The 6-week online MBI comprised short videos, daily guided meditations and automated email reminders. Participants were asked to complete questionnaires at baseline and at 6-week post-randomisation. Study feasibility and acceptability were assessed through recruitment rates, retention and participant feedback. Clinical and psychosocial outcomes were compared between groups using linear mixed models. RESULTS: Sixty-nine (58%) eligible participants were randomised (46 in the intervention; 23 in the control group); mean age was 53.4 (SD 13.1); 54% were female. Study completion rate across both arms was 80%. The intervention was found helpful by 72% of the 32 respondents. The intervention significantly reduced the severity of FCR compared to the control group (mean difference = - 2.55; 95% CI - 4.43, - 0.67; p = 0.008). There was no difference between the intervention and control groups on any of the outcome measures. CONCLUSIONS: This online MBI was feasible and acceptable by people at high risk of melanoma recurrence. It significantly reduced FCR severity in this sample. Patients valued accessing the program at their own pace and convenience. This self-guided intervention has the potential to help survivors cope with emotional difficulties. An adequately powered randomised controlled trial to test study findings is warranted.
Authors: Nicholas Emard; Kathleen A Lynch; Kevin T Liou; Thomas Atkinson; Angela K Green; Bobby Daly; Kelly Trevino; Jun J Mao Journal: JMIR Cancer Date: 2021-06-08
Authors: Kelly M Trevino; Nirupa Raghunathan; Shelly Latte-Naor; Fernanda C G Polubriaginof; Claus Jensen; Thomas M Atkinson; Nicholas Emard; Christina M Seluzicki; Jamie S Ostroff; Jun J Mao Journal: Support Care Cancer Date: 2020-09-09 Impact factor: 3.603
Authors: Eran Ben-Arye; Channing J Paller; Ana Maria Lopez; Shelley White; Eva Pendleton; Gunver S Kienle; Noah Samuels; Nuria Abbawaajii; Lynda G Balneaves Journal: Support Care Cancer Date: 2021-04-14 Impact factor: 3.603
Authors: Natalie Winter; Lahiru Russell; Anna Ugalde; Victoria White; Patricia Livingston Journal: J Med Internet Res Date: 2022-01-12 Impact factor: 5.428
Authors: Patricia M Livingston; Lahiru Russell; Liliana Orellana; Natalie Winter; Michael Jefford; Afaf Girgis; David Austin; Eric O; Cathrine Mihalopoulos; Anna Ugalde; Richard Chambers; Jo Phipps-Nelson; Dishan Herath; Mari Botti; Bodil Rasmussen; Kathryn Whitfield; Maria Ftanou; Allan Ben Smith; Kirsten Pilatti; Sally Sara; Addie Wootten; Kate Gillan; Madhu Singh; David Campbell; Brindha Pillay; Victoria White Journal: BMJ Open Date: 2022-01-12 Impact factor: 2.692
Authors: Diana R Pereira; Eunice R Silva; Carina Carvalho-Maia; Sara Monteiro-Reis; Catarina Lourenço; Rita Calisto; Ricardo João Teixeira; Linda E Carlson; Genevieve Bart; Seppo J Vainio; M Goreti F Sales; Carmen Jerónimo; Rui Henrique Journal: Trials Date: 2022-02-05 Impact factor: 2.279
Authors: Mohamad Baydoun; Chelsea Moran; Andrew McLennan; Katherine-Ann L Piedalue; Devesh Oberoi; Linda E Carlson Journal: Patient Prefer Adherence Date: 2021-06-09 Impact factor: 2.711
Authors: Sapna Oberoi; Jiayu Yang; Roberta L Woodgate; Saroj Niraula; Shantanu Banerji; Sara J Israels; Gary Altman; Sara Beattie; Rasheda Rabbani; Nicole Askin; Abha Gupta; Lillian Sung; Ahmed M Abou-Setta; Ryan Zarychanski Journal: JAMA Netw Open Date: 2020-08-03
Authors: Juraj Matis; Miroslav Svetlak; Alena Slezackova; Marek Svoboda; Rastislav Šumec Journal: J Med Internet Res Date: 2020-11-16 Impact factor: 5.428